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Abstract 
Purpose: 
We recently reported frequent detection of antibiotic-resistant bacteria on the 
oral mucosa during the period of hematopoietic cell transplantation (HCT), and 
suggested an association between oral mucositis and antibiotic-resistant bacterial 
infection. Methicillin-resistant Staphylococcus spp. were frequently detected, and the 
oral cavity may be a reservoir of the gene mediating methicillin resistance, mecA. Here, 
we examined the frequency of mecA carriers in patients undergoing HCT. 
Methods:  
Fifty-nine patients (M: 37, F: 22, 47.3 ± 11.0 y) receiving HCT were enrolled 
in this study. Buccal swab samples were obtained 4 times from day –7 to day +20 
(once/week), and mecA was detected by PCR. Fifty-two subjects without systematic 
disease, who completed dental treatment, especially periodontal treatment (M:21, F:31, 
55.4 ± 14.2 y) were also enrolled as controls, and checked for mecA on the oral mucosa. 
Results: 
Seventy-six percent (45/59) of HCT patients carried mecA at least once in the 
study period (day –7 to +20), while no control subjects had mecA. The frequency of 
mecA carriers was 19.2% from day –7 to –1, while it was significantly increased on 
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days +7 to +13 and +14 to +20, with frequencies of 60.9% and 63.2%, respectively (P < 
0.01, ANOVA). 
Conclusions: 
mecA was detected in oral mucosa of patients undergoing HCT. The high 
detection frequency of staphylococci resistant to penicillin and beta-lactams in our 
recent report was supported.  
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Introduction 
Oral mucositis is one of the most common symptomatic complications 
associated with chemotherapy, especially hematopoietic stem cell transplantation (HCT) 
[12, 13]. Severe mucositis is associated with not only intolerable pain but also the 
possible risk of systemic bacteremia. Oral mucositis is a significant cause of suffering 
and morbidity in patients receiving myeloablative chemotherapy [1]. 
Severe mucositis is associated with a risk of systemic infection related to 
bacteremia. Our recent studies showed that not only normal oral flora but also 
opportunistic bacteria appear on the oral mucosa. Bacterial substitution of mainly 
coagulase-negative staphylococci (CoNS) for streptococci occurred frequently on the 
oral buccal mucosa after HCT, and other bacterial species not usually found in the 
normal flora were also identified [9]. We reported that multidrug-resistant opportunistic 
bacteria appearing in the gingiva may be involved in fatal sepsis [11]. Furthermore, 
many antibiotic-resistant bacteria were detected in the oral cavity after HCT, especially 
during the period in which the severity of oral mucositis reaches its peak [10]. CoNS 
and Staphylococcus aureus with penicillin and beta-lactam resistance were detected 
[10]. 
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Penicillin and beta-lactam resistance among staphylococci are mediated by 
point mutations in penicillin binding proteins (PBPs) [2]. Methicillin resistance in 
staphylococci is mediated by the mecA gene complex, which is located on a unique 
molecular vector called the staphylococcal chromosome cassette (SCCmec) [3]. 
SCCmecs carry mobility genes and integrate in a site-specific manner into a highly 
conserved locus in the Staphylococcus chromosome.  
The present study was performed to determine the distribution of oral mucosal 
bacteria with mecA in patients undergoing hematopoietic cell transplantation. 
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Materials and Methods 
Subjects 
Fifty-nine patients (M: 37, F: 22, 47.3 ± 11.0 y) receiving HCT at Okayama 
University Hospital from 2011 to 2012 were enrolled in this study. The diseases of these 
patients are shown in Table 1. Autologous HCT, conventional allogeneic HCT, and 
reduced-intensity stem cell transplantation (RIST) were administered to 12 (M: 8, F: 4, 
56.8 ± 9.5 y), 13 (M: 9, F: 4, 42.4 ± 10.6 y), and 34 (M: 20, F: 14, 54.6 ± 11.4 y) 
patients, respectively. Fifty-two patients without systematic diseases, who visited the 
Department of Periodontics, Okayama University Hospital (M: 21, F: 31, 55.4 ± 14.2 y), 
were also enrolled as controls. A total of 111 subjects were enrolled in the study. 
Informed consent for examination of oral bacteria was obtained from each subject, and 
the Ethics Committee of Okayama University Graduate School of Medicine, Dentistry, 
and Pharmaceutical Sciences approved this study (No. 457). 
Oral management 
Intensive oral care was performed for all HCT subjects as our previous report 
[10]. All HCT subjects received referred to dentists, and necessary dental treatment was 
completed before HCT. All subjects received instruction regarding self-management of 
oral hygiene; tooth brushing after every meal and before going to bed, and oral rinsing 
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with normal saline solution every 3 h during the day was also indicated. Nurses, dental 
hygienists, and dentists performed these oral managements in cases in which the 
patient’s condition was poor. No antibiotics rinses were used. 
All control subjects were in maintenance phase after completion of dental 
treatment, especially for periodontal treatment. Therefore, their oral hygiene was well 
maintained. Subjects who had systematic diseases were excluded. All subjects 
confirmed that they had not received antibiotic treatment for at least 3 months prior to 
enrolling in the study. 
General infection control for HCT subjects 
 All HCT patients were isolated in a room equipped with a laminar airflow 
system and received trimethoprim-sulfamethoxazole as prophylaxis against 
Pneumocystis carinii. Fluoroquinolone for prophylaxis against bacterial infection and 
fluconazole for prophylaxis against fungal infection were administered orally. 
Prophylaxis against herpes virus infection with acyclovir was also given. Neutropenic 
fever was managed according to the guidelines of Hughes et al. [5]. Briefly, empirical 
antibiotic therapy was administered promptly in all neutropenic patients at the onset of 
fever and in afebrile patients who were neutropenic but who had signs or symptoms 
compatible with infection. A fourth-generation cephalosporin (e.g., cefepime) or 
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carbapenem (e.g., meropenem) was administered intravenously as empirical antibiotic 
therapy. G-CSF (lenograstim 5 µg/kg/day or filgrastim 300 µg/m2) was given 
intravenously for 60 min starting on day 1 or 5, and was continued until the absolute 
neutrophil count exceeded 500/µL. 
Collection of bacterial samples 
Microbial samples were obtained from HCT patients about 2 h after breakfast 
by swabbing from the whole surface of the buccal mucosa regardless of whether 
mucositis was observed. Collection of bacterial samples was performed four times (day 
–7 to –1; day 0 to +6; day +7 to +13; day +14 to +20) for each patient (a total of 236 
times in 59 patients). However, samples could not be collected 27 times because of the 
patents’ conditions. A total of 209 samples were subjected to mecA detection 
procedures. 
Microbial samples were also obtained from control subjects once just after a 
check-up and before any dental intervention at our hospital. Thus, the dental treatment 
on the check-up day could not affect the results of this study. A total of 52 samples from 
52 control subjects were subjected to mecA detection procedures. 
Detection of mecA 
1) Bacterial DNA extraction 
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Cotton swab samples were suspended in 1 mL of PBS(–) (Gibco BRL, Grand 
Island, NY). Aliquots of 500 μL from each suspension were transferred into new tubes 
and pelleted. Pelleted samples were resuspended in 200 μL of InstaGene matrix 
(Bio-Rad Laboratories, Hercules, CA) to extract total bacterial DNA. Aliquots of 
extracted DNA were subjected to polymerase chain reaction (PCR).  
2) Confirmation of bacterial DNA 
First, to confirm bacterial DNA was obtained appropriately, PCR amplification 
of the 16S ribosomal RNA gene (16S rDNA) was performed. The PCR mixture (25 μL) 
contained 12.5 μL of 2×AmpliTaq Gold® 360 Master Mix (Applied Biosystems, 
Carlsbad, CA), 10 pmol of forward and reverse universal primers (forward: 5'-GTG 
STG CAY GGY TGT CGT CA-3', reverse: 5'-ACG TCR TCC MCA CCT TCC TC- 3') 
[7], and a 2.5-μL aliquot of extracted DNA. PCR cycles were as follows: initial cycle of 
95°C for 10 min; 35 cycles of 95°C for 1 min, 56°C for 1 min and 72°C for 2 min; and a 
final extension at 72°C for 5 min. Amplified products were subjected to 2% agarose 
electrophoresis, and 120-bp DNA fragments were confirmed by ultraviolet light after 
ethidium bromide staining. 
3) mecA detection by PCR 
mecA detection by PCR was performed as described previously [4]. The PCR 
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mixture (25 μL) contained 12.5 μL of 2×AmpliTaq Gold® 360 Master Mix (Applied 
Biosystems), 10 pmol of primers (forward: 5'- TGC TAT CCA CCC TCA AAC AGG -3', 
reverse: 5'- AAC GTT GTA ACC ACC CCA AGA - 3'), and a 2.5-μL aliquot of 
extracted DNA. PCR cycles were as follows: initial cycle of 95°C for 10 min; 35 cycles 
of 95°C for 30 s, 52°C for 30 s and 72°C for 1 min; and a final extension at 72°C for 7 
min. Amplified products were subjected to 2% agarose electrophoresis, and 284-bp 
DNA fragments were confirmed by ultraviolet light after ethidium bromide staining.  
Statistical analysis 
Differences in mecA carrier frequencies were compared by Fisher’s exact test 
or ANOVA using the statistical software IBM® SPSS® Statistics Version 21 (IBM 
Corporation, NY). In all analyses, P < 0.05 was taken to indicate significance. 
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Results 
Confirmation of bacterial DNA by PCR detection of 16S rDNA 
The 16S rDNA PCR-amplified fragment was detected from 191 samples out of 
209 prepared DNA samples from 59 HCT patients. The 16S rDNA was not detected in 
18 samples, and mecA was also not detected from all these 18 samples in following 
analysis. These 18 samples were considered that bacterial gene sample could not be 
collected appropriately because something technical error could be occurred in the 
sample correction because of patients’ condition, therefore excluded from further 
analysis. Collect rate of bacterial DNA from oral mucosal swab was 91.4%. The 16S 
rDNA fragment was successfully amplified by PCR from all samples from the control 
group (n = 52). 
Frequencies of mecA carriers in groups of HCT patients and control subjects 
The frequency of mecA carriers in whom mecA was detected at least once during 
the study period (day –7 to +20 from HCT) was compared with that of the control group. 
The results were shown in Table 2 and Figure 1. Seventy-six percent (45/59) of HCT 
patients carried mecA, while none of the control subjects had mecA. The difference in 
frequency of mecA carriers between HCT patients and control subjects was significant 
(P < 0.01 Fisher’s exact test). 
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Transition of the frequency of mecA carriers in HCT patients 
The transition of the frequency of mecA carriers on the oral mucosa before and 
after HCT is shown in Figure 1. The detection frequencies of mecA increased 
significantly with time after HCT. The frequency of mecA carriers was 19.2% on day –7 
to –1 from HCT, while it was significantly increased from day +7 to +13 and day +14 to 
+20, with frequencies of 60.9% and 63.2%, respectively (P < 0.01, ANOVA).  
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Discussion 
The results of the present study indicated the presence of mecA in the oral 
cavity after HCT. The detection frequencies of mecA increased significantly with time 
after HCT. These results support those of our recent study indicating the detection of 
many CoNS and S. aureus with penicillin and beta-lactam resistance in the oral cavity 
after HCT [6].  
In our recent study on antibiotic sensitivity of bacteria on the oral mucosa after 
HCT, CoNS with high degrees of resistance to penicillins and beta-lactams and 
methicillin-resistant S. aureus (MRSA) were detected [6]. We expected mecA detection 
based on our recent study using the culture method, while the frequency of mecA 
carriers on the oral mucosa was very high, over 60% from day +7 to +20, which was 
beyond our expectation. This could be because a fourth-generation cephalosporin was 
mainly administered intravenously as empirical antibiotic therapy. A more in depth 
analysis of these patients compared to HCT patients who were negative before HCT as 
well as the patients who got positive during treatment might be interesting and might 
corroborate our assumption that the administration of a fourth-generation cephalosporin 
was responsible for this increase in mecA detection. We will try to perform multi-center 
study to increase subject number and would like to confirm our assumption. 
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The mecA gene complex is located on a unique molecular vector called the 
staphylococcal chromosome cassette (SCCmec) [3]. SCCmecs are considered to be 
transferred into S. aureus from a coagulase-negative species [6, 14]. The tendencies of 
mecA detection frequency may differ between institutes because of their policies of 
antibiotic use, while we speculate that the oral cavity just before and after HCT may be 
a reservoir and could be a transfer space of the genes regulating antibiotic resistance as 
mecA. Recent research strongly suggests that oral hygiene may also be a reasonable 
strategy to control methicillin-resistant CoNS to eventually lower the MRSA burden in 
medical facilities [8]. Maintenance of good oral hygiene after HCT may contribute to 
reducing the presence of genes regulating antibiotic resistance in the oral cavity and 
antibiotic-resistant bacterial infections.  
In conclusion, mecA, which mediates penicillin and beta-lactam resistance, was 
detected from the oral mucosa immediate before and after HCT. The high detection 
frequency of staphylococci with resistance to penicillins and beta-lactams in our recent 
report was supported at the molecular level.  
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Figure legends 
Figure 1.  
Frequency of HCT patients in whom mecA was detected at least once during the HCT 
period, and transition of the frequency of mecA carriers in HCT patients.  
The difference in frequency of mecA carriers between HCT patients and control subjects 
was significant (#P<0.01, Fisher’s exact test) (†Frequency of mecA carriers in whom 
mecA was detected at least once during day –7 to +20 from HCT). The detection 
frequencies of mecA increased significantly with time after HCT. The frequency of 
mecA carriers was 19.2% at day –7 to –1 from HCT, while it increased significantly at 
day +7 to +13 and day +14 to +20, with frequencies of 60.9% and 63.2%, respectively 
(*P < 0.01, ANOVA). 
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Tables 
Table 1. Diseases of patients 
Diseases Type of HCT Total 
Autologous Allogeneic 
Conventional RIST 
Acute myelogenous leukemia   
Acute lymphoblastic leukemia 
Chronic myelogenous leukemia 
Malignant lymphoma 
Aplastic anemia 
 8 9 17 
 3 1 4 
 1 1 2 
12 1 12 25 
  2 2 
Myelodysplastic syndromes   8 8 
Myelofibrosis   1 1 
Total 12 13 34 59 
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Table 2. Frequency of mecA carriers in whom mecA was detected at least once 
during the study period (day –7 to +20 from HCT) and in control subjects 
 
 
mec A 
Total 
+ – 
HCT group 
control group 
45 (76.3%) 
0 (0%) 
14 (23.7%) 
52 (100%) 
59 
52 
total 45 66 111 
(*P < 0.01, Fisher’s exact test)
* 
23 
 
Table 3. Transition of the frequency of mecA carriers in HCT patients  
 
Days from HCT 
mec A 
total 
+ – 
-7 to -1 10 (19.2 %) 42 (80.8 %) 52 
0 to +6 20 (36.4 %) 35 (63.6 %) 55 
+7 to +13 28 (60.9 %)* 18 (39.1 %) 46 
+14 to +20 24 (63.2 %)* 14 (36.8 %) 38 
(*P < 0.01, ANOVA, compared with day -7 to -1) 
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